{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:55:19Z","timestamp":1791406519978,"version":"4.3.3"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.seizure.2026.09.016","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:24:15Z","timestamp":1789971855000},"page":"78-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Initial experience of bortezomib in cryptogenic new-onset refractory status epilepticus: a case series"],"prefix":"10.1016","volume":"143","author":[{"given":"Tejas","family":"Shivarthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripadma","family":"PV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheeran","family":"Kannoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-0933","authenticated-orcid":false,"given":"Siby","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.seizure.2026.09.016_bib0001","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1111\/epi.17391","article-title":"International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) including Febrile Infection-Related Epilepsy Syndrome (FIRES): Summary and Clinical Tools","volume":"63","author":"Wickstrom","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.09.016_bib0002","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2018.09.018","article-title":"New onset refractory status epilepticus (NORSE)","volume":"68","author":"Sculier","year":"2019","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.seizure.2026.09.016_bib0003","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/epi.17933","article-title":"Second-line immunotherapy in new onset refractory status epilepticus","volume":"65","author":"Hanin","year":"2024","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2026.09.016_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.seizure.2026.09.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000396","article-title":"Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy","volume":"4","author":"Iizuka","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.seizure.2026.09.016_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/jnnp-2024-334285","article-title":"Prognosis prediction and immunotherapy optimisation for cryptogenic new-onset refractory status epilepticus","volume":"96","author":"Jang","year":"2025","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"6","key":"10.1016\/j.seizure.2026.09.016_bib0007","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2026.09.016_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2025.06.022","article-title":"Retrospective multicenter study on cryptogenic NORSE\/FIRES patients treated with anakinra","volume":"130","author":"Giussani","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.09.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577586","article-title":"Bortezomib in anti-N-Methyl-D-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review","volume":"356","author":"Dinoto","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.seizure.2026.09.016_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.seizure.2012.09.011","article-title":"Plasma exchange in cryptogenic new onset refractory status epilepticus","volume":"22","author":"Li","year":"2013","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.seizure.2026.09.016_bib0011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"1","key":"10.1016\/j.seizure.2026.09.016_bib0012","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/epi4.12454","article-title":"Super refractory status in a case of Febrile Infection-Related Epilepsy Syndrome due to hemophagocytic lymphocytic histiocytosis","volume":"6","author":"Meenakshi-Sundaram","year":"2021","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2026.09.016_bib0013","doi-asserted-by":"crossref","unstructured":"Kilmer J, Ransley G, Murphy E, Hanna MG, Pitceathly RDS, Rajakulendran S, Pizzamiglio C. The Role of Metabolic Testing in the Diagnostic Evaluation of Adult NORSE: A Retrospective, Single-Centre Study. Eur J Neurol. 2025;32(6):e70218. doi: 10.1111\/ene.70218. PMID: 40470573; PMCID: PMC12138435.","DOI":"10.1111\/ene.70218"},{"key":"10.1016\/j.seizure.2026.09.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106870","article-title":"Experience of bortezomib use in refractory autoimmune neurological disorders","volume":"105","author":"Popova","year":"2026","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.seizure.2026.09.016_bib0015","first-page":"3450","article-title":"Long-term outcome in new onset refractory status epilepticus: a retrospective study","volume":"271","author":"Stretti","year":"2024","journal-title":"J Neurol"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:26:37Z","timestamp":1791404797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":15,"alternative-id":["S1059131126002803"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.09.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial experience of bortezomib in cryptogenic new-onset refractory status epilepticus: a case series","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}